Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Figure 1. Target map of the PathScan® EGFR Signaling Antibody Array Kit (Fluorescent Readout) #12785. † A reduction in a signal associated with E746-A750 deletion mutant was observed after treatment of cells with the small molecule inhibitors Gefitinib #4765 and Erlotinib #5083.

Learn more about how we get our images

Figure 2. A-431 cells were grown to 90% confluency and then serum-starved overnight. Cells were stimulated with Human Epidermal Growth Factor (hEGF) #8916 (100 ng/ml, 5 min). Cell extracts were prepared and analyzed using the PathScan® EGFR Signaling Antibody Array Kit (Fluorescent Readout) #12785. Panel A shows images that were acquired using the LI-COR® Biosciences Odyssey® imaging system. Panel B shows raw values of quantified fluorescence intensity. Pixel intensity was quantified using the LI-COR® Image Studio v2.0 array analysis software.

Learn more about how we get our images

Figure 3. Calu-3 cells were grown to 90% confluency and lysed using a buffer containing (P) or devoid of (NP) phosphatase inhibitors. Cell extracts were prepared and analyzed using the PathScan® EGFR Signaling Antibody Array Kit (Fluorescent Readout) #12785. Panel A shows images that were acquired using the LI-COR® Biosciences Odyssey® imaging system. Panel B shows raw values of quantified fluorescence intensity for a selected set of targets. Pixel intensity was quantified using the LI-COR® Image Studio v2.0 array analysis software.

Learn more about how we get our images

Figure 4. HCC827 and H3255 are two non-small cell lung cancer (NSCLC) cell lines carrying two different gefitinib-sensitive mutants of EGFR: E746-A750 deletion in exon 19 and L858R point mutation, respectively. Cells were grown to 90% confluency and then lysed using a buffer containing (P) or devoid of (NP) phosphatase inhibitors. Cell extracts were prepared and analyzed using the PathScan® EGFR Signaling Antibody Array Kit (Fluorescent Readout) #12785. Images were acquired using the LI-COR® Biosciences Odyssey® imaging system. Fluorescence intensity was quantified using the LI-COR® Image Studio v2.0 array analysis software. Heatmap analysis was generated using MultiExperiment Viewer (MeV) analysis software (14) using the raw fluorescence intensity values.

Learn more about how we get our images

Figure 5. (A) HCC827 cells were treated with Gefitinib #4765, Erlotinib #5083, Crizotinib #4401, or Foretinib, as indicated, for 16 hours. The total amounts of EGFR (wt and mutant) or the EGFR (E746-A750) deletion mutant were quantified using the PathScan® EGFR Signaling Antibody Array Kit (Fluorescent Readout) #12785 (bar graph). The same samples were also analyzed by western blot using EGF Receptor (E746-A750del Specific) 6B6 XP® Rabbit mAb #2085 (upper) and EGF Receptor (15F8) Rabbit mAb #4405 (lower). Note: The western blot shows that sandwich immunoassay detection in the EGFR (E746-A750) deletion mutant specific assay (bar graph) may be sensitive to EGFR inhibitors targeting the active site. (B) HCC827 cells were treated with increasing concentrations of Gefitinib #4765 for 2.5 hours. Tyrosine phosphorylation levels of the indicated sites in EGFR or the EGFR (E746-A750) deletion mutant were quantified using the PathScan® EGFR Signaling Antibody Array Kit (Fluorescent Readout) #12785.

Learn more about how we get our images
Image
Page

PathScan® EGFR Signaling Array Kit (Fluorescent Readout) #12785 Protocol

A. Preparing Cell Lysates

  1. Thaw 10X Cell Lysis Buffer (#9803) and mix thoroughly. Prepare 1X Cell Lysis Buffer by diluting 10X Cell Lysis Buffer in deionized water. Supplement Cell Lysis Buffer with phenylmethylsulfonyl fluoride (PMSF) (#8553) to a final concentration of 1 mM, or a cocktail of protease inhibitors such as #5871 or #5872. Keep lysis buffer on ice.
  2. Remove media and wash cells once with ice-cold 1X PBS.
  3. Remove PBS and add ice-cold Cell Lysis Buffer (#7018). For adherent cells, use 0.5 ml Cell Lysis Buffer for each plate (10 cm in diameter). Incubate on ice for 2 min.
  4. Tilt the plate, scrape cells, and collect the lysate into a clean microcentrifuge tube.
  5. Optional step: microcentrifuge the lysate at maximum speed for 3 min at 4°C and transfer the supernatant to a new tube. The supernatant is the cell lysate. This step is usually not required but can help remove any particles or large cell debris, if present. Lysate may be used immediately or stored at -80°C in single-use aliquots.
  6. Immediately before performing the assay, dilute lysates to 0.2–1.0 mg/ml in Array Diluent Buffer. Set aside on ice.

B. Assay Procedure

  1. Bring glass slides and blocking buffer to room temperature before use.
  2. Prepare 1X Array Wash Buffer by diluting 20X Array Wash Buffer in deionized water. Dilute 2.5 ml of 20X Array Wash Buffer with 47.5 ml of deionized water. Label as 1X Array Wash Buffer and keep at room temperature.
  3. Prepare both 1X Detection Antibody Cocktails A and B as follows:
    • For running only 1 slide:

      **NOTE: Cocktails A and B must be prepared in two separate tubes.

      Dilute 75 μl of 10X Detection Antibody Cocktails A and B each with 675 μl of Array Diluent Buffer into two separate appropriately labeled tubes. Keep 1X Detection Antibody Cocktails A and B on ice.

    • For running 2 slides:

      **NOTE: Cocktails A and B must be prepared in two separate tubes

      Dilute 150 μl of 10X Detection Antibody Cocktails A and B each with 1350 μl of Array Diluent Buffer into two separate appropriately labeled tubes. Keep 1X Detection Antibody Cocktails A and B on ice.

  4. Prepare 1X DyLight™ 680-linked Streptavidin as follows:
    • For running only 1 slide: Dilute 150 μl of 10X DyLight 680™-linked Streptavidin with 1350 μl of Array Diluent Buffer into an appropriately labeled tube. Keep the 1X DyLight 680®-linked Streptavidin on ice.
    • For running 2 slides: Dilute 300 μl of 10X DyLight 680™-linked Streptavidin with 2700 μl of Array Diluent Buffer into an appropriately labeled tube. Keep the 1X DyLight 680™-linked Streptavidin on ice.
  5. Affix the multi-well gasket to the glass slide (see figure below):
    1. Place the multi-well gasket face-down on the benchtop (the silicone layer should be facing up). Remove the protective plastic film.
    2. Carefully place the glass slide on top of the multi-well gasket with the nitro- cellulose pads facing down while aligning the pads with the openings in the gasket. The orientation line should appear in the upper left hand corner when the slide is oriented vertically.
    3. Insert the metal clip into the groove in the gasket and rotate the clip into the locked position. Ensure that the clip is on the same side as the orientation line on the slide.

      Note: One of the clips has a small dot etched onto the upper rib to assist with pad designation (see slide assembly photos).

    4. Slide the clip into place.
    5. Snap the second metal clip to the other side of the assembly in the same manner and slide into place.
    6. The assembled array is ready to use.
  6. Add 100 μl Array Blocking Buffer to each well and cover with sealing tape. Incubate for 15 min at room temperature on an orbital shaker.

    Note: Do not allow the pads to dry out at any time during the assay

  7. Decant Array Blocking Buffer by gently flicking out the liquid into a sink or other appropriate waste receptacle. Add 50-75 μl diluted lysate making sure to add each individual sample to both sub-arrays A (left column pads) and sub-array B (right column pads). Cover array with sealing tape and incubate for 2 hr at room temperature (or overnight at 4°C) on an orbital shaker.
  8. Decant well contents by gently flicking out the liquid into a sink or other appropriate waste receptacle. Add 100 μl 1X Array Wash Buffer to each well and incubate for 5 min at room temperature on an orbital shaker. Repeat three more times. Decant well contents.
  9. Add 75 μl 1X Detection Antibody Cocktails A, to sub-arrays A (left column pads), and B, to sub-arrays B (right column pads). Cover with sealing tape and incubate for 1 hr at room temperature on an orbital shaker.
  10. Wash 4 times for 5 min with 100 μl 1X Array Wash Buffer as in step 8.

    Note: From this point on, keep slide protected from the light.

  11. Add 75 μl 1X DyLight 680™-linked Streptavidin to each well and cover with sealing tape. Incubate for 30 min at room temperature on an orbital shaker.
  12. Wash 4 times for 5 min with 100 μl 1X Array Wash Buffer as in step 8.
  13. Remove multi-well gasket by pulling the bottom of the metal clips away from the center of the slide, then peeling the slide and gasket apart.
  14. Place the slide face up in a plastic dish (a clean pipette tip box cover works well). Wash once for 10 sec with 10 ml deionized water.
  15. Remove slide from plastic dish and allow to dry completely.
  16. Capture an image of the slide using a fluorescent digital imaging system capable of exciting at 680 nm and detecting at 700 nm. Quantify spot intensities using commercially available array image analysis software.
Slide Assembly Photos

DyLight 680™ is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

Product Includes Quantity Cap Color
Array Slides - EGFR Signaling Array Kit  2 Ea
16-Well Gasket 2 Ea
Sealing Tape 2 sheets
20X Array Wash Buffer 15 ml White
Array Blocking Buffer 5 ml Red
Array Diluent Buffer 15 ml Blue
Detection Ab Cocktail B(10X) - EGFR Signaling Array Kit 150 µl Green
DyLight 680TM-linked Streptavidin (10X) 300 µl Brown
Cell Lysis Buffer (10X) 9803 15 ml Clear

Product Usage Information

Storage: Kit should be stored at 4°C with the exception of Lysis Buffer, which is stored at –20°C (packaged separately).

Product Description

The PathScan® EGFR Signaling Antibody Array Kit (Fluorescent Readout) uses glass slides as the planar surface and is based upon the sandwich immunoassay principle. The array kit allows for the simultaneous detection of phosphorylated EGFR, HER2, c-Met on distinct sites as well as a number of key signaling nodes found downstream of these RTKs. Target-specific capture antibodies have been spotted in duplicate onto nitrocellulose-coated glass slides. Each kit contains two slides allowing for the interrogation of 16 different samples. To improve assay performance the content of this array is split between two sub-arrays. The pads on left-hand side of each slide belong to sub-array A while the pads on the right-hand side of each slide belong to sub-array B. Cell lysates are incubated on the slide followed by a biotinylated detection antibody cocktail A or cocktail B (each cocktail for the corresponding sub-array). Streptavidin-conjugated DyLight® 680 is then used to visualize the bound detection antibody. A fluorescent image of the slide can then be captured with a digital imaging system and spot intensities quantified using array analysis software.


Specificity / Sensitivity

PathScan® EGFR Signaling Antibody Array Kit (Fluorescent Readout) detects the target proteins as specified on the Array Target Map. No substantial cross-reactivity has been observed between targets. This kit is optimized for cell lysates diluted to a total protein concentration between 0.2 and 1 mg/ml (see kit protocol).

Note: Detection in the EGFR (E746-A750) deletion mutant specific assay may be sensitive to EGFR inhibitors targeting the active site. (See Figure 5).


Species Reactivity: Human

The Epidermal Growth Factor Receptor (EGFR) is a receptor tyrosine kinase (RTK) that constitutes an important disease driver, as well as a validated drug target. The potency of EGFR in driving tumorigenesis can be attributed to its pleiotropic intracellular signaling. Activated EGFR initiates a wide range of signaling modules and switches such as the Ras - Erk/MAP kinase, Akt, Src, Stat, and PKC. Two of the most common EGFR mutations ocurring in lung cancer are the E746-A750 deletion and L858R point mutation. This array utilizes unique antibodies made by Cell Signaling Technology that are sensitive to each of these EGFR mutants, allowing specific target detection in cell extracts.

EGFR can interact and heterodimerize with other RTKs. HER2 (also known as ErbB2) is an oncogenic RTK belonging to the EGFR/HER family of RTKs and is an important heterodimerization partner of all HER family members. Another prominent heterodimerization partner of EGFR is c-Met. c-Met is an RTK serving as a receptor for the hepatocyte growth factor (HGF). c-Met can induce cell scattering, migration, and invasion. It has been shown that c-Met is responsible for some cases of tumor resistance to EGFR-targeted therapies and is a contributing factor to tumor metastasis.

PLCγ is a phosphoinositide-specific phospholipase. EGFR can activate PLCγ that, in turn, hydrolyzes phosphoinositide phospholipids residing within the inner leaflet of the plasma membrane. This hydrolysis generates two important second messengers: inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 causes calcium mobilization from intracellular storage pools, while DAG (together with calcium) activates PKC. MEK1 is a dual-specificity protein kinase and serves as the MAP kinase kinase for Erk1 and Erk2. Upon EGFR activation, MEK1 is phosphorylated by Raf and, in turn, phosphorylates the Erk kinases at Thr202 and Tyr204, leading to their activation. Activated Erk MAP kinase is a major signaling node with a multitude of substrates and primarily transmits growth and proliferation signals. Akt is another important protein kinase downstream of EGFR. Akt is activated by many RTKs and has a large number of intracellular substrates. Akt generates anabolic growth and survival signals. Stat3 is activated in response to EGFR stimulation, as well as in response to activation of a variety of cytokine receptors. Stat3 is a well-established oncogene that is also a transcription factor.

The oncogenic signals generated by activated EGFR are a focus of intense drug discovery efforts. It has become clear that in many cases a single agent inhibiting only one target is unable to cause tumor cell death in vivo. To monitor the blockade of EGFR signals alongside markers of cell death, cleaved PARP is included in this array. PARP is an enzyme involved in DNA repair. As a part of the apoptotic process, PARP is irreversibly inactivated by endoproteolytic cleavage executed by activated cell death proteases, such as caspase-3 and caspasae-7.


1.  Yarden, Y. (2001) Eur J Cancer 37 Suppl 4, S3-8.

2.  Hackel, P.O. et al. (1999) Curr Opin Cell Biol 11, 184-9.

3.  Zwick, E. et al. (1999) Trends Pharmacol Sci 20, 408-12.

4.  Avraham, R. and Yarden, Y. (2011) Nat Rev Mol Cell Biol 12, 104-17.

5.  Levitzki, A. (2003) Lung Cancer 41 Suppl 1, S9-14.

6.  Sharma, S.V. and Settleman, J. (2009) Exp Cell Res 315, 557-71.

7.  Knowles, L.M. et al. (2009) Clin Cancer Res 15, 3740-50.

8.  Hudelist, G. et al. (2003) Breast Cancer Res Treat 80, 353-61.

9.  Engelman, J.A. et al. (2007) Science 316, 1039-43.

10.  Comoglio, P.M. (2001) Nat Cell Biol 3, E161-2.

11.  Benedettini, E. et al. (2010) Am J Pathol 177, 415-23.

12.  Guo, A. et al. (2008) Proc Natl Acad Sci U S A 105, 692-7.

13.  Klein, S. and Levitzki, A. (2009) Curr Opin Cell Biol 21, 185-93.

14.  Saeed, A.I. et al. (2003) Biotechniques 34, 374-8.


Entrez-Gene Id 207 , 208 , 10000 , 1956 , 5595 , 5594 , 2064 , 5604 , 5605 , 4233 , 142 , 5335 , 6774
Swiss-Prot Acc. P31749 , P31751 , Q9Y243 , P00533 , P27361 , P28482 , P04626 , Q02750 , P36507 , P08581 , P09874 , P19174 , P40763

Protein Specific References

Germack R and Dickenson JM (2000) Br J Pharmacol 130, 867–74

Wick MJ et al. (2000) J Biol Chem 275, 40400–6

Guizzetti M and Costa LG (2001) Neuroreport 12, 1639–42

Brognard J et al. (2001) Cancer Res 61, 3986–97

Maira SM et al. (2001) Science 294, 374–80

Schönherr E et al. (2001) J Biol Chem 276, 40687–92

Hill MM et al. (2001) J Biol Chem 276, 25643–6

Rane MJ et al. (2001) J Biol Chem 276, 3517–23

Dhawan P et al. (2002) Cancer Res 62, 7335–42

Conus NM et al. (2002) J Biol Chem 277, 38021–8

Sano H et al. (2002) J Biol Chem 277, 19439–47

Egawa K et al. (2002) J Biol Chem 277, 38863–9

Kisseleva MV et al. (2002) J Biol Chem 277, 6266–72

Barry FA and Gibbins JM (2002) J Biol Chem 277, 12874–8

Ikonomov OC et al. (2002) Endocrinology 143, 4742–54

Rani MR et al. (2002) J Biol Chem 277, 38456–61

Ho R et al. (2002) Cancer Res 62, 6462–6

Wan X and Helman LJ (2003) Oncogene 22, 8205–11

Fukuda T et al. (2003) J Biol Chem 278, 51324–33

Kim HH et al. (2003) FASEB J 17, 2163–5

Min YH et al. (2004) Cancer Res 64, 5225–31

Tazzari PL et al. (2004) Br J Haematol 126, 675–81

Matsuzaki H et al. (2004) Biochemistry 43, 4284–93

Wolfrum S et al. (2004) Arterioscler Thromb Vasc Biol 24, 1842–7

Kaneko Y et al. (2004) J Cell Sci 117, 407–15

Esfandiarei M et al. (2004) J Virol 78, 4289–98

Baudhuin LM et al. (2004) FASEB J 18, 341–3

Dietze EC et al. (2004) Oncogene 23, 3851–62

Wu T et al. (2004) Mol Cancer Ther 3, 299–307

Honjo S et al. (2005) DNA Cell Biol 24, 141–7

Karlsson HK et al. (2005) Diabetes 54, 1459–67

Viniegra JG et al. (2005) J Biol Chem 280, 4029–36

Le XF et al. (2005) J Biol Chem 280, 2092–104

Smith E and Frenkel B (2005) J Biol Chem 280, 2388–94

Edwards LA et al. (2005) Oncogene 24, 3596–605

Karlsson HK et al. (2005) Diabetes 54, 1692–7

Kippenberger S et al. (2005) J Biol Chem 280, 3060–7

Jung HS et al. (2005) Mol Endocrinol 19, 2748–59

Khundmiri SJ et al. (2006) Am J Physiol Cell Physiol 291, C1247–57

Hers I and (2007) Blood 110, 4243–52

Ananthanarayanan B et al. (2007) J Biol Chem 282, 36634–41

Zunder ER et al. (2008) Cancer Cell 14, 180–92

Grenegård M et al. (2008) J Biol Chem 283, 18493–504

Abubaker J et al. (2009) Mol Cancer 8, 51

Chen PL and Easton AS (2011) Curr Neurovasc Res 8, 14–24

Van Aller GS et al. (2011) Biochem Biophys Res Commun 406, 194–9

Ou YH et al. (2011) Mol Cell 41, 458–70

Uesugi A et al. (2011) Cancer Res 71, 5765–78

Wang S et al. (2012) PLoS One 7, e37427

Glidden EJ et al. (2012) J Biol Chem 287, 581–8

Shih MC et al. (2012) Oncogene 31, 2389–400

Misra UK and Pizzo SV (2012) J Cell Biochem 113, 1488–500

Germack R and Dickenson JM (2000) Br J Pharmacol 130, 867–74

Wick MJ et al. (2000) J Biol Chem 275, 40400–6

Guizzetti M and Costa LG (2001) Neuroreport 12, 1639–42

Brognard J et al. (2001) Cancer Res 61, 3986–97

Maira SM et al. (2001) Science 294, 374–80

Schönherr E et al. (2001) J Biol Chem 276, 40687–92

Hill MM et al. (2001) J Biol Chem 276, 25643–6

Rane MJ et al. (2001) J Biol Chem 276, 3517–23

Dhawan P et al. (2002) Cancer Res 62, 7335–42

Conus NM et al. (2002) J Biol Chem 277, 38021–8

Sano H et al. (2002) J Biol Chem 277, 19439–47

Egawa K et al. (2002) J Biol Chem 277, 38863–9

Kisseleva MV et al. (2002) J Biol Chem 277, 6266–72

Barry FA and Gibbins JM (2002) J Biol Chem 277, 12874–8

Ikonomov OC et al. (2002) Endocrinology 143, 4742–54

Rani MR et al. (2002) J Biol Chem 277, 38456–61

Ho R et al. (2002) Cancer Res 62, 6462–6

Wan X and Helman LJ (2003) Oncogene 22, 8205–11

Fukuda T et al. (2003) J Biol Chem 278, 51324–33

Kim HH et al. (2003) FASEB J 17, 2163–5

Min YH et al. (2004) Cancer Res 64, 5225–31

Tazzari PL et al. (2004) Br J Haematol 126, 675–81

Matsuzaki H et al. (2004) Biochemistry 43, 4284–93

Wolfrum S et al. (2004) Arterioscler Thromb Vasc Biol 24, 1842–7

Kaneko Y et al. (2004) J Cell Sci 117, 407–15

Esfandiarei M et al. (2004) J Virol 78, 4289–98

Baudhuin LM et al. (2004) FASEB J 18, 341–3

Dietze EC et al. (2004) Oncogene 23, 3851–62

Wu T et al. (2004) Mol Cancer Ther 3, 299–307

Honjo S et al. (2005) DNA Cell Biol 24, 141–7

Karlsson HK et al. (2005) Diabetes 54, 1459–67

Viniegra JG et al. (2005) J Biol Chem 280, 4029–36

Le XF et al. (2005) J Biol Chem 280, 2092–104

Smith E and Frenkel B (2005) J Biol Chem 280, 2388–94

Edwards LA et al. (2005) Oncogene 24, 3596–605

Karlsson HK et al. (2005) Diabetes 54, 1692–7

Kippenberger S et al. (2005) J Biol Chem 280, 3060–7

Jung HS et al. (2005) Mol Endocrinol 19, 2748–59

Khundmiri SJ et al. (2006) Am J Physiol Cell Physiol 291, C1247–57

Hers I and (2007) Blood 110, 4243–52

Ananthanarayanan B et al. (2007) J Biol Chem 282, 36634–41

Zunder ER et al. (2008) Cancer Cell 14, 180–92

Grenegård M et al. (2008) J Biol Chem 283, 18493–504

Abubaker J et al. (2009) Mol Cancer 8, 51

Chen PL and Easton AS (2011) Curr Neurovasc Res 8, 14–24

Van Aller GS et al. (2011) Biochem Biophys Res Commun 406, 194–9

Ou YH et al. (2011) Mol Cell 41, 458–70

Uesugi A et al. (2011) Cancer Res 71, 5765–78

Wang S et al. (2012) PLoS One 7, e37427

Glidden EJ et al. (2012) J Biol Chem 287, 581–8

Shih MC et al. (2012) Oncogene 31, 2389–400

Misra UK and Pizzo SV (2012) J Cell Biochem 113, 1488–500

Germack R and Dickenson JM (2000) Br J Pharmacol 130, 867–74

Wick MJ et al. (2000) J Biol Chem 275, 40400–6

Guizzetti M and Costa LG (2001) Neuroreport 12, 1639–42

Brognard J et al. (2001) Cancer Res 61, 3986–97

Maira SM et al. (2001) Science 294, 374–80

Schönherr E et al. (2001) J Biol Chem 276, 40687–92

Hill MM et al. (2001) J Biol Chem 276, 25643–6

Rane MJ et al. (2001) J Biol Chem 276, 3517–23

Dhawan P et al. (2002) Cancer Res 62, 7335–42

Conus NM et al. (2002) J Biol Chem 277, 38021–8

Sano H et al. (2002) J Biol Chem 277, 19439–47

Egawa K et al. (2002) J Biol Chem 277, 38863–9

Kisseleva MV et al. (2002) J Biol Chem 277, 6266–72

Barry FA and Gibbins JM (2002) J Biol Chem 277, 12874–8

Ikonomov OC et al. (2002) Endocrinology 143, 4742–54

Rani MR et al. (2002) J Biol Chem 277, 38456–61

Ho R et al. (2002) Cancer Res 62, 6462–6

Wan X and Helman LJ (2003) Oncogene 22, 8205–11

Fukuda T et al. (2003) J Biol Chem 278, 51324–33

Kim HH et al. (2003) FASEB J 17, 2163–5

Min YH et al. (2004) Cancer Res 64, 5225–31

Tazzari PL et al. (2004) Br J Haematol 126, 675–81

Matsuzaki H et al. (2004) Biochemistry 43, 4284–93

Wolfrum S et al. (2004) Arterioscler Thromb Vasc Biol 24, 1842–7

Kaneko Y et al. (2004) J Cell Sci 117, 407–15

Esfandiarei M et al. (2004) J Virol 78, 4289–98

Baudhuin LM et al. (2004) FASEB J 18, 341–3

Dietze EC et al. (2004) Oncogene 23, 3851–62

Wu T et al. (2004) Mol Cancer Ther 3, 299–307

Honjo S et al. (2005) DNA Cell Biol 24, 141–7

Karlsson HK et al. (2005) Diabetes 54, 1459–67

Viniegra JG et al. (2005) J Biol Chem 280, 4029–36

Le XF et al. (2005) J Biol Chem 280, 2092–104

Smith E and Frenkel B (2005) J Biol Chem 280, 2388–94

Edwards LA et al. (2005) Oncogene 24, 3596–605

Karlsson HK et al. (2005) Diabetes 54, 1692–7

Kippenberger S et al. (2005) J Biol Chem 280, 3060–7

Jung HS et al. (2005) Mol Endocrinol 19, 2748–59

Khundmiri SJ et al. (2006) Am J Physiol Cell Physiol 291, C1247–57

Hers I and (2007) Blood 110, 4243–52

Ananthanarayanan B et al. (2007) J Biol Chem 282, 36634–41

Zunder ER et al. (2008) Cancer Cell 14, 180–92

Grenegård M et al. (2008) J Biol Chem 283, 18493–504

Abubaker J et al. (2009) Mol Cancer 8, 51

Chen PL and Easton AS (2011) Curr Neurovasc Res 8, 14–24

Van Aller GS et al. (2011) Biochem Biophys Res Commun 406, 194–9

Ou YH et al. (2011) Mol Cell 41, 458–70

Uesugi A et al. (2011) Cancer Res 71, 5765–78

Wang S et al. (2012) PLoS One 7, e37427

Glidden EJ et al. (2012) J Biol Chem 287, 581–8

Shih MC et al. (2012) Oncogene 31, 2389–400

Misra UK and Pizzo SV (2012) J Cell Biochem 113, 1488–500

Johnson AL et al. (2001) Biol Reprod 64, 1566–74

Zhang M and Riedel H (2009) J Cell Biochem 107, 65–75

Johnson AL et al. (2001) Biol Reprod 64, 1566–74

Zhang M and Riedel H (2009) J Cell Biochem 107, 65–75

Johnson AL et al. (2001) Biol Reprod 64, 1566–74

Zhang M and Riedel H (2009) J Cell Biochem 107, 65–75

Heimberger AB et al. (2002) Clin Cancer Res 8, 3496–502

Chen X and Resh MD (2002) J Biol Chem 277, 49631–7

Ravid T et al. (2002) J Biol Chem 277, 31214–9

Westover EJ et al. (2003) J Biol Chem 278, 51125–33

Agazie YM and Hayman MJ (2003) Mol Cell Biol 23, 7875–86

Saito T et al. (2004) Endocrinology 145, 4232–43

Pao W et al. (2004) Proc Natl Acad Sci U S A 101, 13306–11

Mattila E et al. (2005) Nat Cell Biol 7, 78–85

Tanos B and Pendergast AM (2006) J Biol Chem 281, 32714–23

Huang F et al. (2006) Mol Cell 21, 737–48

Wu SL et al. (2006) Mol Cell Proteomics 5, 1610–27

Kannangai R et al. (2006) Mod Pathol 19, 1456–61

Sonnweber B et al. (2006) J Clin Pathol 59, 255–9

Riggins RB et al. (2006) Cancer Res 66, 7007–15

Huang F et al. (2007) Proc Natl Acad Sci U S A 104, 16904–9

Tong J et al. (2009) Mol Cell Proteomics 8, 2131–44

Goh LK et al. (2010) J Cell Biol 189, 871–83

Hall EH et al. (2011) Cell Signal 23, 1972–7

Huang WC et al. (2011) J Biol Chem 286, 20558–68

Cotton CU et al. (2013) Traffic 14, 337–54

Heimberger AB et al. (2002) Clin Cancer Res 8, 3496–502

Chen X and Resh MD (2002) J Biol Chem 277, 49631–7

Ravid T et al. (2002) J Biol Chem 277, 31214–9

Westover EJ et al. (2003) J Biol Chem 278, 51125–33

Agazie YM and Hayman MJ (2003) Mol Cell Biol 23, 7875–86

Saito T et al. (2004) Endocrinology 145, 4232–43

Pao W et al. (2004) Proc Natl Acad Sci U S A 101, 13306–11

Mattila E et al. (2005) Nat Cell Biol 7, 78–85

Tanos B and Pendergast AM (2006) J Biol Chem 281, 32714–23

Huang F et al. (2006) Mol Cell 21, 737–48

Wu SL et al. (2006) Mol Cell Proteomics 5, 1610–27

Kannangai R et al. (2006) Mod Pathol 19, 1456–61

Sonnweber B et al. (2006) J Clin Pathol 59, 255–9

Riggins RB et al. (2006) Cancer Res 66, 7007–15

Huang F et al. (2007) Proc Natl Acad Sci U S A 104, 16904–9

Tong J et al. (2009) Mol Cell Proteomics 8, 2131–44

Goh LK et al. (2010) J Cell Biol 189, 871–83

Hall EH et al. (2011) Cell Signal 23, 1972–7

Huang WC et al. (2011) J Biol Chem 286, 20558–68

Cotton CU et al. (2013) Traffic 14, 337–54

Heimberger AB et al. (2002) Clin Cancer Res 8, 3496–502

Chen X and Resh MD (2002) J Biol Chem 277, 49631–7

Ravid T et al. (2002) J Biol Chem 277, 31214–9

Westover EJ et al. (2003) J Biol Chem 278, 51125–33

Agazie YM and Hayman MJ (2003) Mol Cell Biol 23, 7875–86

Saito T et al. (2004) Endocrinology 145, 4232–43

Pao W et al. (2004) Proc Natl Acad Sci U S A 101, 13306–11

Mattila E et al. (2005) Nat Cell Biol 7, 78–85

Tanos B and Pendergast AM (2006) J Biol Chem 281, 32714–23

Huang F et al. (2006) Mol Cell 21, 737–48

Wu SL et al. (2006) Mol Cell Proteomics 5, 1610–27

Kannangai R et al. (2006) Mod Pathol 19, 1456–61

Sonnweber B et al. (2006) J Clin Pathol 59, 255–9

Riggins RB et al. (2006) Cancer Res 66, 7007–15

Huang F et al. (2007) Proc Natl Acad Sci U S A 104, 16904–9

Tong J et al. (2009) Mol Cell Proteomics 8, 2131–44

Goh LK et al. (2010) J Cell Biol 189, 871–83

Hall EH et al. (2011) Cell Signal 23, 1972–7

Huang WC et al. (2011) J Biol Chem 286, 20558–68

Cotton CU et al. (2013) Traffic 14, 337–54

Heimberger AB et al. (2002) Clin Cancer Res 8, 3496–502

Chen X and Resh MD (2002) J Biol Chem 277, 49631–7

Ravid T et al. (2002) J Biol Chem 277, 31214–9

Westover EJ et al. (2003) J Biol Chem 278, 51125–33

Agazie YM and Hayman MJ (2003) Mol Cell Biol 23, 7875–86

Saito T et al. (2004) Endocrinology 145, 4232–43

Pao W et al. (2004) Proc Natl Acad Sci U S A 101, 13306–11

Mattila E et al. (2005) Nat Cell Biol 7, 78–85

Tanos B and Pendergast AM (2006) J Biol Chem 281, 32714–23

Huang F et al. (2006) Mol Cell 21, 737–48

Wu SL et al. (2006) Mol Cell Proteomics 5, 1610–27

Kannangai R et al. (2006) Mod Pathol 19, 1456–61

Sonnweber B et al. (2006) J Clin Pathol 59, 255–9

Riggins RB et al. (2006) Cancer Res 66, 7007–15

Huang F et al. (2007) Proc Natl Acad Sci U S A 104, 16904–9

Tong J et al. (2009) Mol Cell Proteomics 8, 2131–44

Goh LK et al. (2010) J Cell Biol 189, 871–83

Hall EH et al. (2011) Cell Signal 23, 1972–7

Huang WC et al. (2011) J Biol Chem 286, 20558–68

Cotton CU et al. (2013) Traffic 14, 337–54

Heimberger AB et al. (2002) Clin Cancer Res 8, 3496–502

Chen X and Resh MD (2002) J Biol Chem 277, 49631–7

Ravid T et al. (2002) J Biol Chem 277, 31214–9

Westover EJ et al. (2003) J Biol Chem 278, 51125–33

Agazie YM and Hayman MJ (2003) Mol Cell Biol 23, 7875–86

Saito T et al. (2004) Endocrinology 145, 4232–43

Pao W et al. (2004) Proc Natl Acad Sci U S A 101, 13306–11

Mattila E et al. (2005) Nat Cell Biol 7, 78–85

Tanos B and Pendergast AM (2006) J Biol Chem 281, 32714–23

Huang F et al. (2006) Mol Cell 21, 737–48

Wu SL et al. (2006) Mol Cell Proteomics 5, 1610–27

Kannangai R et al. (2006) Mod Pathol 19, 1456–61

Sonnweber B et al. (2006) J Clin Pathol 59, 255–9

Riggins RB et al. (2006) Cancer Res 66, 7007–15

Huang F et al. (2007) Proc Natl Acad Sci U S A 104, 16904–9

Tong J et al. (2009) Mol Cell Proteomics 8, 2131–44

Goh LK et al. (2010) J Cell Biol 189, 871–83

Hall EH et al. (2011) Cell Signal 23, 1972–7

Huang WC et al. (2011) J Biol Chem 286, 20558–68

Cotton CU et al. (2013) Traffic 14, 337–54

Heimberger AB et al. (2002) Clin Cancer Res 8, 3496–502

Chen X and Resh MD (2002) J Biol Chem 277, 49631–7

Ravid T et al. (2002) J Biol Chem 277, 31214–9

Westover EJ et al. (2003) J Biol Chem 278, 51125–33

Agazie YM and Hayman MJ (2003) Mol Cell Biol 23, 7875–86

Saito T et al. (2004) Endocrinology 145, 4232–43

Pao W et al. (2004) Proc Natl Acad Sci U S A 101, 13306–11

Mattila E et al. (2005) Nat Cell Biol 7, 78–85

Tanos B and Pendergast AM (2006) J Biol Chem 281, 32714–23

Huang F et al. (2006) Mol Cell 21, 737–48

Wu SL et al. (2006) Mol Cell Proteomics 5, 1610–27

Kannangai R et al. (2006) Mod Pathol 19, 1456–61

Sonnweber B et al. (2006) J Clin Pathol 59, 255–9

Riggins RB et al. (2006) Cancer Res 66, 7007–15

Huang F et al. (2007) Proc Natl Acad Sci U S A 104, 16904–9

Tong J et al. (2009) Mol Cell Proteomics 8, 2131–44

Goh LK et al. (2010) J Cell Biol 189, 871–83

Hall EH et al. (2011) Cell Signal 23, 1972–7

Huang WC et al. (2011) J Biol Chem 286, 20558–68

Cotton CU et al. (2013) Traffic 14, 337–54

Syme CA et al. (2005) J Biol Chem 280, 11281–8

Syme CA et al. (2005) J Biol Chem 280, 11281–8

Li Z et al. (2001) J Biol Chem 276, 42226–32

Li Z et al. (2001) J Biol Chem 276, 42226–32

Dankort D et al. (2001) Mol Cell Biol 21, 1540–51

Ren Z and Schaefer TS (2002) J Biol Chem 277, 38486–93

Marone R et al. (2004) Nat Cell Biol 6, 515–22

Montgomery RB et al. (2005) Cancer Res 65, 650–6

Bose R et al. (2006) Proc Natl Acad Sci U S A 103, 9773–8

Xu W et al. (2007) Mol Cell Biol 27, 220–8

Northey JJ et al. (2008) Mol Cell Biol 28, 3162–76

Frogne T et al. (2009) Breast Cancer Res 11, R11

Dankort D et al. (2001) Mol Cell Biol 21, 1540–51

Ren Z and Schaefer TS (2002) J Biol Chem 277, 38486–93

Marone R et al. (2004) Nat Cell Biol 6, 515–22

Montgomery RB et al. (2005) Cancer Res 65, 650–6

Bose R et al. (2006) Proc Natl Acad Sci U S A 103, 9773–8

Xu W et al. (2007) Mol Cell Biol 27, 220–8

Northey JJ et al. (2008) Mol Cell Biol 28, 3162–76

Frogne T et al. (2009) Breast Cancer Res 11, R11

Dankort D et al. (2001) Mol Cell Biol 21, 1540–51

Ren Z and Schaefer TS (2002) J Biol Chem 277, 38486–93

Marone R et al. (2004) Nat Cell Biol 6, 515–22

Montgomery RB et al. (2005) Cancer Res 65, 650–6

Bose R et al. (2006) Proc Natl Acad Sci U S A 103, 9773–8

Xu W et al. (2007) Mol Cell Biol 27, 220–8

Northey JJ et al. (2008) Mol Cell Biol 28, 3162–76

Frogne T et al. (2009) Breast Cancer Res 11, R11

Bondzi C et al. (2000) Oncogene 19, 5030–3

Bondzi C et al. (2000) Oncogene 19, 5030–3

Bondzi C et al. (2000) Oncogene 19, 5030–3

Maulik G et al. (2002) J Cell Mol Med 6, 539–53

Lock LS et al. (2003) J Biol Chem 278, 30083–90

Palka HL et al. (2003) J Biol Chem 278, 5728–35

Hov H et al. (2004) Clin Cancer Res 10, 6686–94

Deheuninck J et al. (2009) Cell Signal 21, 1455–63

Pavone LM et al. (2011) Cell Signal 23, 1961–71

Nakayama M et al. (2013) Cytokine 62, 446–52

Maulik G et al. (2002) J Cell Mol Med 6, 539–53

Lock LS et al. (2003) J Biol Chem 278, 30083–90

Palka HL et al. (2003) J Biol Chem 278, 5728–35

Hov H et al. (2004) Clin Cancer Res 10, 6686–94

Deheuninck J et al. (2009) Cell Signal 21, 1455–63

Pavone LM et al. (2011) Cell Signal 23, 1961–71

Nakayama M et al. (2013) Cytokine 62, 446–52

Ng J and Cantrell D (1997) J Biol Chem 272, 24542–9

Schuringa JJ et al. (2000) Blood 95, 3765–70

Duarte RF and Frank DA (2000) Blood 96, 3422–30

Schuringa JJ et al. (2001) Oncogene 20, 5350–8

Deb A et al. (2001) EMBO J 20, 2487–96

Abe K et al. (2001) Oncogene 20, 3464–74

Kopantzev Y et al. (2002) Oncogene 21, 6791–800

Sun S and Steinberg BM (2002) J Gen Virol 83, 1651–8

Hwang JH et al. (2003) Mol Endocrinol 17, 1155–66

Lo RK et al. (2003) J Biol Chem 278, 52154–65

Liu H et al. (2003) Blood 102, 344–52

Lo RK and Wong YH (2004) Mol Pharmacol 65, 1427–39

Wang R et al. (2005) J Biol Chem 280, 11528–34

Ray S et al. (2005) Gastroenterology 129, 1616–32

Yuan ZL et al. (2005) Science 307, 269–73

Liu AM et al. (2006) J Biol Chem 281, 35812–25

Zhang X et al. (2007) Proc Natl Acad Sci U S A 104, 4060–4

Ohbayashi N et al. (2007) Biol Pharm Bull 30, 1860–4

Nadiminty N et al. (2007) Biochem Biophys Res Commun 359, 379–84

Duechting A et al. (2008) J Virol 82, 7942–52

Chen CL et al. (2008) Mol Cancer 7, 78

Hatziapostolou M et al. (2011) Cell 147, 1233–47

Sestito R et al. (2011) FASEB J 25, 916–27

Gupta M et al. (2012) Leukemia 26, 1356–64

Ng J and Cantrell D (1997) J Biol Chem 272, 24542–9

Schuringa JJ et al. (2000) Blood 95, 3765–70

Duarte RF and Frank DA (2000) Blood 96, 3422–30

Schuringa JJ et al. (2001) Oncogene 20, 5350–8

Deb A et al. (2001) EMBO J 20, 2487–96

Abe K et al. (2001) Oncogene 20, 3464–74

Kopantzev Y et al. (2002) Oncogene 21, 6791–800

Sun S and Steinberg BM (2002) J Gen Virol 83, 1651–8

Hwang JH et al. (2003) Mol Endocrinol 17, 1155–66

Lo RK et al. (2003) J Biol Chem 278, 52154–65

Liu H et al. (2003) Blood 102, 344–52

Lo RK and Wong YH (2004) Mol Pharmacol 65, 1427–39

Wang R et al. (2005) J Biol Chem 280, 11528–34

Ray S et al. (2005) Gastroenterology 129, 1616–32

Yuan ZL et al. (2005) Science 307, 269–73

Liu AM et al. (2006) J Biol Chem 281, 35812–25

Zhang X et al. (2007) Proc Natl Acad Sci U S A 104, 4060–4

Ohbayashi N et al. (2007) Biol Pharm Bull 30, 1860–4

Nadiminty N et al. (2007) Biochem Biophys Res Commun 359, 379–84

Duechting A et al. (2008) J Virol 82, 7942–52

Chen CL et al. (2008) Mol Cancer 7, 78

Hatziapostolou M et al. (2011) Cell 147, 1233–47

Sestito R et al. (2011) FASEB J 25, 916–27

Gupta M et al. (2012) Leukemia 26, 1356–64


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
PathScan is a trademark of Cell Signaling Technology, Inc.
DyLight is a trademark of Thermo Fisher Scientific, Inc. and its subsidiaries.
LI-COR is a registered trademark of LI-COR, Inc.
Odyssey is a registered trademark of LI-COR, Inc.

12785
PathScan® EGFR Signaling Antibody Array Kit (Fluorescent Readout)